T
Overview
TRIUMF is Canada's particle accelerator center in Vancouver, established in 1968. It uses a large accelerator complex to conduct research across particle and nuclear physics, isotope science, materials science, and life sciences, and to develop technologies such as medical isotopes. Its strength comes from national-scale accelerator infrastructure, multidisciplinary collaboration with Canadian universities and industry, and work that spans fundamental discovery to practical applications. Its goal is to advance science, improve health and economic outcomes, and strengthen Canadian leadership through world-class facilities and collaborations.
Work here?Claim your company
Simplify's take
What believers are saying
- BC announced $32 million for TRIUMF-linked radiopharmacy infrastructure in 2026.
- TRIUMF hosts Minister Joly's July 2025 announcement of $1.3 billion for research.
- The 2026 General Fusion diagnostic project expands TRIUMF into commercial fusion instrumentation.
What critics are saying
- Federal funding ends March 31, 2030; renewal failure would cripple operations.
- BC Cancer's new cyclotron and radiopharmacy lab will compete for isotope talent and throughput.
- Heavy dependence on government grants leaves hiring, capital projects, and research fragile.
What makes TRIUMF unique
- TRIUMF operates Canada's national particle accelerator lab with a 2025-2030 NRC contribution.
- Its cyclotron supports subatomic physics, isotope production, and radiopharmaceutical development.
- The 2025 CNRS partnership creates the NPAT lab for nuclear physics and astrophysics.
Help us improve and share your feedback! Did you find this helpful?